![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/08/2909562/0/en/NewAmsterdam-Pharma-Completes-Enrollment-in-Pivotal-Phase-3-TANDEM-Clinical-Trial-Evaluating-Fixed-Dose-Combination-of-Obicetrapib-plus-Ezetimibe-in-Patients-with-HeFH-and-or-ASCVD.html
https://www.globenewswire.com/news-release/2024/07/03/2908427/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/11/2896737/0/en/NewAmsterdam-Pharma-Announces-Issuance-of-Composition-of-Matter-Patent-for-Obicetrapib-by-the-United-States-Patent-and-Trademark-Office.html
https://www.globenewswire.com/news-release/2024/06/07/2895562/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/29/2889826/0/en/NewAmsterdam-Pharma-to-Participate-in-Upcoming-Investor-Conferences-in-June.html
https://www.globenewswire.com/news-release/2024/05/21/2885534/0/en/NewAmsterdam-Pharma-to-Present-New-Clinical-and-Preclinical-Data-Highlighting-Obicetrapib-s-Impact-on-Key-Risk-Factors-for-Cardiovascular-Disease-at-Upcoming-Medical-Meetings.html
https://www.globenewswire.com/news-release/2024/05/09/2878723/0/en/NewAmsterdam-Pharma-Provides-Corporate-Update-and-Reports-First-Quarter-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/03/2875340/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/02/2874162/0/en/NewAmsterdam-Pharma-to-Host-R-D-Day-with-Key-Opinion-Leaders-on-May-16-2024.html
https://www.globenewswire.com/news-release/2024/04/09/2859907/0/en/NewAmsterdam-Pharma-Enrolls-Over-9-000-Patients-in-Pivotal-Phase-3-PREVAIL-Global-Cardiovascular-Outcome-Trial-Evaluating-the-Effect-of-Obicetrapib-in-Patients-with-Established-Ath.html